Mallinckrodt’s extended-release pain drug meets main goal of study

By Vrinda Manocha (Reuters) – Specialty pharmaceutical company Mallinckrodt Plc said its experimental painkiller significantly reduced the intensity of pain in patients who had undergone a surgical removal of bunions. The drug, MNK-795, showed statistically significant improvement in pain scores over 48 hours, compared to a placebo in a late-stage trial. MNK-795 would have to be taken only once a day unlike other generic combinations in the market. It is also designed to resist abuse. …